More-EUROPA

We work towards a more efficient use of real-world data in the development, registration and assessment of medicinal products in Europe

While randomized controlled trials (RCTs) remain the mainstay in drug development, approval, and reimbursement, the potential of real world data (RWD) to contribute to the understanding of drug effects is increasingly realized.

The aim of our project is to develop, implement and establish evidentiary standards and methods to address the data and evidentiary needs of regulatory authorities and health technology assessment (HTA) bodies towards a more efficient use of RWD for the development, registration and assessment of medicinal products in Europe.